brieftenax therapeutics says companys board is continuing its review of strategic alternatives  reuters discover thomson reutersfinancialgovernment solutionslegalreuters news agencyrisk management solutionstax  accountingblog answers oninnovation  thomson reutersdirectory of siteslogincontactsupportin  hoursbrieftenax therapeutics says companys board is continuing its review of strategic alternativesrussiatrumpearningshealthcarecyberriskfutureofmoneyenergyenvironmentsectionsbusinessmarketsworldpoliticstechcommentarybreakingviewsmoneylifepicturesreuters tvdiscover thomson reutersfinancialgovernment solutionslegalreuters news agencyrisk management solutionstax  accountingblog answers oninnovation  thomson reutersdirectory of siteslogincontactsupportfeaturednorth koreanorth korea tests another icbm putting us cities in rangehealthcare republicans try to pick up the piecesusmajority of americans support transgender military servicepicturesreuters tveditionunited statesafricaamérica latinaعربيargentinabrasilcanadadeutschlandespañafranceindiaitaliaméxicoроссияunited kingdomunited statesmarket newsjuly     pm  in  hoursbrieftenax therapeutics says companys board is continuing its review of strategic alternatives min readjuly  reuters  tenax therapeutics inc  tenax therapeutics provides regulatory update on levosimendan  tenax therapeutics inc says companys board of directors is continuing its review of strategic alternatives  tenax therapeutics inc  after a review of further analyses fda has requested an additional clinical trial  tenax therapeutics inc  company is reviewing clinical regulatory and financial options with regard to levosimendan program in us and canada source text for eikon further company coverage  narrowbrowserandphonemediumbrowserandportraittabletlandscapetabletmediumwidebrowserwidebrowserandlargermediumbrowserandlandscapetabletmediumwidebrowserandlargerabovephoneportraittabletandaboveaboveportraittabletlandscapetabletandabovelandscapetabletandmediumwidebrowserportraittabletandbelowlandscapetabletandbelowappsnewslettersreuters plusadvertising guidelinescookiesterms of useprivacyall quotes delayed a minimum of  minutes see here for a complete list of exchanges and delays  reuters all rights reserved tenax therapeutics provides regulatory update on levosimendan  business wire tenax therapeutics provides regulatory update on levosimendan july    pm eastern daylight time morrisville ncbusiness wiretenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today provides a regulatory update following discussions with the us food and drug administration fda and health canada regarding a regulatory path forward for levosimendan in may  the company participated in a prenda meeting with the fda to discuss the possibility of submitting an nda for levosimendan in two indications treatment of patients undergoing coronary artery bypass grafting cabg to reduce the risk of low cardiac output syndrome lcos and treatment of patients with acute decompensated heart failure adhf for improvement in symptoms after a review of further analyses the fda has requested an additional clinical trial given the size and scope of such a trial the company is reviewing clinical regulatory and financial options with regard to the levosimendan program in the us and canada the company’s board of directors is continuing its review of strategic alternatives with the assistance of their financial advisors at ladenburg thalmann  co inc strategic alternatives under review include but are not limited to a merger a business combination a strategic investment into the company or a purchase license or other acquisition of assets this process may not result in any transaction and the company does not intend to disclose additional details unless and until it has entered into a specific transaction about levosimendan levosimendan is a calcium sensitizer that works through a unique triple mechanism of action it initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure it was discovered and developed by orion pharma orion corporation of espoo finland and is currently approved in over  countries for this indication and not available in the united states tenax therapeutics acquired the north american rights to develop and commercialize levosimendan from phyxius pharma about tenax therapeutics tenax therapeutics inc is a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market for more information visit wwwtenaxtheracom caution regarding forwardlooking statements this news release contains certain forwardlooking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release the forwardlooking statements are subject to a number of risks and uncertainties including but not limited to matters beyond the company’s control that could lead to delays in the clinical study delays in new product introductions and customer acceptance of these new products and other risks and uncertainties as described in the company’s filings with the securities and exchange commission including in its transition report on form k filed on march   its quarterly report on form q filed on may   as well as its other filings with the sec the company disclaims any intent or obligation to update these forwardlooking statements beyond the date of this release statements in this press release regarding management’s future expectations beliefs goals plans or prospects constitute forwardlooking statements within the meaning of the private securities litigation reform act of  contacts stern investor relations incwill o‘connor willsternircom release summary tenax therapeutics inc nasdaq tenx provides regulatory update on levosimendan following discussions with fda additional clinical trial needed contacts stern investor relations incwill o‘connor willsternircom search advanced news search advanced news search log in sign up tenx key statistics  tenax therapeutics inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close tenax therapeutics inc nasdaq tenx go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus tenax therapeutics inc after hours  quotes are delayed by  min jul    pm tenx quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   company description tenax therapeutics inc is a pharmaceutical company which focuses on identifying developing and commercializing novel therapeutic products for the critical care market the company intends to develop levosimendan a calcium sensitizer for intravenous use in hospitalized patients with acutely deco tenax therapeutics inc is a pharmaceutical company which focuses on identifying developing and commercializing novel therapeutic products for the critical care market the company intends to develop levosimendan a calcium sensitizer for intravenous use in hospitalized patients with acutely decompensated heart failure tenax therapeutics was founded on may   and is headquartered in morrisville nc valuation pe current  pe ratio with extraordinary items  price to book ratio  enterprise value to ebitda  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability capital structure officers and executives name age officer since title mr michael b jebsen   president ceo cfo  treasurer mr doug randall   executive vpcommercial  business operations ms nancy j hecox   secretary evplegal affairs  general counsel dr douglas hay   executive vice presidentregulatory affairs dr ronald r blanck   chairman insider actions – purchase – sale  – number of transactions  newslatestcompanyustenx marketwatch news on tenx analogic shares decline after revenue miss  pm sept    wallace witkowski dow rallies sp  russell  at record  pm march    anora mahmudova oxygen biotherapeutics fda lifts hold on oxycyte  am march    marketwatchcom the rollercoaster stock in health care that is oxygen biotherapeutics  pm nov    russ britt big earnings friday rick’s cabaret ocean power  am dec    marketwatch oxygen biotherapeutics names new chairman  am oct    marketwatchcom oxygen bio chief faked resume audit body shows  pm sept    marketwatchcom newsnonmarketwatchcompanyustenx other news on tenx tenax therapeutics tenx ceo john kelley on q  results  earnings call transcript  am march    seeking alpha k tenax therapeutics inc  pm march    edgar online  edg  q k tenax therapeutics lead product candidate flunks latestate study shares plummet   pm jan    seeking alpha hottest services stocks now – evi qhc apti evbg  pm dec    investorplacecom tenax completes enrollment in latestage levosimendan study  am nov    seeking alpha tenax therapeutics tenx ceo john kelley on q  results  earnings call transcript  pm nov    seeking alpha tenax therapeutics reports q results  am nov    seeking alpha q tenax therapeutics inc  pm nov    edgar online  edg  q k  biotechnology stocks to sell now  am oct    investorplacecom biggest movers in services stocks now – carb aya ln qhc  am oct    investorplacecom hottest services stocks now – mobl pcyg snmx aris  am oct    investorplacecom biggest movers in services stocks now – crm renn aris uri  am oct    investorplacecom hottest services stocks now – nxtd avxl twtr tmh  am oct    investorplacecom hottest services stocks now – snmx ment syna qhc  am sept    investorplacecom hottest services stocks now – aroc ziop cyh mb  pm sept    investorplacecom hottest services stocks now – twlo fve rpd team  pm sept    investorplacecom  biotechnology stocks to sell now  am sept    investorplacecom biggest movers in services stocks now – clbs tenx mtls dtlk  pm sept    investorplacecom  biotechnology stocks to sell now  am sept    investorplacecom hottest services stocks now – tsri gigm zdge dwch  pm sept    investorplacecom loading more headlines at a glance tenax therapeutics inc one copley parkway suite  morrisville north carolina  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for tenx newspressreleasecompanyustenx press releases on tenx tenax therapeutics provides regulatory update on levosimendan  pm today pm july    businesswire  bzx how these biotech stocks are faring  idera pharma biotime rxi pharma and tenax therapeutics  am may    pr newswire  prf tenax meets with fda to discuss positive mortality data and potential levosimendan nda submission  pm may    businesswire  bzx tenax therapeutics and alcobra find rough waters ahead  am april    accesswire tenax therapeutics announces review of strategic alternatives and business update  pm april    businesswire  bzx tenax therapeutics announces yearend  financial results and provides corporate update  am march    businesswire  bzx investor network invites you to the tenax therapeutics fiscal year  business review and update conference call and webcast on tuesday march    pm march    accesswire tenax therapeutics to discuss yearend  financial results and provide business update  pm march    businesswire  bzx tenax therapeutics announces topline results from phase  levocts trial in cardiac surgery  am jan    businesswire  bzx biotech ma activity expected to rise in  latest reports on tenax therapeutics and ziopharm oncology  am jan    accesswire financialbuzzcom advances in technology applied in the biotech sector  am jan    pr newswire  prf tenax therapeutics inc review of clinical trials and financials  am jan    accesswire tenax therapeutics announces completion of enrollment for phase  levocts trial in cardiac surgery  am nov    businesswire  bzx tenax therapeutics announces third quarter  financial results and provides corporate update  am nov    businesswire  bzx investor calendar invites you to the tenax therapeutics third quarter  business review and update on thursday november    pm nov    accesswire tenax therapeutics to discuss third quarter  financial results and provide business update  pm nov    businesswire  bzx tenax therapeutics provides clinical update for lead candidate levosimendan  am oct    businesswire  bzx tenax therapeutics announces second quarter  financial results and provides corporate update  am aug    businesswire  bzx tenax therapeutics to discuss second quarter  financial results and provide business update  pm aug    businesswire  bzx trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages phere’s one trump fan who might make you some money pwhy it might be time to invest in the companies amazon is destroying loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  tenax therapeutics inc  nasdaqtenx  stock quote  news  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street tenax therapeutics inc tenx follow    nasdaq  health care jul    pm edt prev close  open  day lowhigh     wk lowhigh    volume k avg volume k exchange nasdaq shares outstanding m market cap m eps  pe ratio na div  yield na na trade with jim cramer  days free latest news tenax therapeutics provides regulatory update on levosimendan tenax meets with fda to discuss positive mortality data and potential levosimendan nda submission tenax therapeutics announces review of strategic alternatives and business update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today provided an update related to its business apr    pm edt tenax therapeutics announces yearend  financial results and provides corporate update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced financial results for the full year mar    am edt tenax therapeutics to discuss yearend  financial results and provide business update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that the company will host a mar    pm edt these  stocks under  could light up soon heres a technical look at how to trade several under  stocks that could trigger big breakout trades soon feb    pm est tenax therapeutics announces topline results from phase  levocts trial in cardiac surgery tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced topline results from its phase  jan    am est tenax therapeutics announces completion of enrollment for phase  levocts trial in cardiac surgery tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that it has completed patient nov    am est tenax therapeutics announces third quarter  financial results and provides corporate update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced financial results for the third nov    am est tenax therapeutics to discuss third quarter  financial results and provide business update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that the company will host a nov    pm edt tenax therapeutics provides clinical update for lead candidate levosimendan tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today reported a comprehensive clinical development oct    am edt tenax therapeutics announces second quarter  financial results and provides corporate update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced financial results for the second aug    am edt tenax therapeutics to discuss second quarter  financial results and provide business update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that the company will host a aug    pm edt tenax therapeutics announces first quarter  financial results and provides corporate update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced financial results for the first may    am edt  tenax therapeutics to discuss first quarter  financial results and provide business update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that the company will host a may    am edt tenax therapeutics announces  transitional report and provides corporate update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today provided a business update around the companys mar    am edt tenax therapeutics to provide  transitional report and business update tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that the company will host a mar    pm est tenax therapeutics to present at cowen and company th annual health care conference tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that john kelley chief executive mar    pm est tenax therapeutics to present at leerink partners th annual global healthcare conference tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that john kelley chief executive feb    am est tenax therapeutics provides update of phase  levocts trial for lcos tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today provided an update for its ongoing phase  feb    am est tenax therapeutics highlights completion of enrollment for leopards trial by imperial college london tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today highlighted that imperial college london has dec    am est tenax therapeutics announces second quarter fiscal year  financial results tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced financial results for the second dec    am est tenax therapeutics to provide corporate update and discuss second quarter fiscal year  financial results on december   tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that the company will host a dec    pm est tenax therapeutics provides clinical update for lead candidate levosimendan tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today provided a detailed clinical progress update oct    am edt tenax therapeutics to present at ladenburg thalmann  healthcare conference tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that john kelley chief executive sep    am edt tenax therapeutics announces first quarter fiscal year  financial results tenax therapeutics inc nasdaqtenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced financial results for the first sep    am edt tenax therapeutics partners with sepsis alliance to raise awareness of sepsis and septic shock tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that it has become a national event sep    am edt tenax therapeutics to provide corporate update and discuss first quarter fiscal year  financial results on september   tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that the company will host a sep    am edt tenax therapeutics announces nomination of james mitchum to board of directors tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that james mitchum has been nominated aug    am edt tenax therapeutics to present at  wedbush pacgrow healthcare conference tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today announced that john kelley chief executive aug    am edt next load more from our partners tenax therapeutics upgraded to buy from neutral at ladenburg the fly tenax therapeutics reports fy results seekingalpha midday gainers  losers seekingalpha tenax therapeutics lead product candidate flunks latestate study shares plummet  seekingalpha healthcare  top  gainers  losers as of  am seekingalpha midday gainers  losers seekingalpha healthcare  top  gainers  losers as of  am seekingalpha healthcare  top gainers  losers as of  am seekingalpha midday gainers  losers seekingalpha tenax completes enrollment in latestage levosimendan study seekingalpha tenax therapeutics reports q results seekingalpha tenax therapeutics beats by  seekingalpha healthcare  top  gainers  losers as of  am seekingalpha tenax therapeutics net loss improves in q seekingalpha tenax therapeutics beats by  seekingalpha trending tesla is a cult stock jim cramer says can apple show amazon what earnings should look like ipod nano shuffle are dead here are  other discontinued apple products jim cramer nails starbucks big decline warns again of downside to  heres why snaps stock could be in for another big plunge on monday advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers company  tenax therapeutics tenax therapeutics inc is a specialty pharmaceutical company focused on identifying developing and commercializing a portfolio of products for the critical care market our business strategy includes  core elements search develop and commercialize search we intend to identify and acquire innovative proprietary pharmaceutical products that represent high value commercial opportunities for the north american market we do not intend to conduct basic research ourselves the relative efficiency of our “search” strategy enables us to focus the majority of our resources on developing and commercializing innovative products that other companies have discovered develop we intend to develop pharmaceutical products that meet significant unmet needs of critical care patients in north america our significant clinical development and regulatory experience makes tenax therapeutics an ideal partner for companies who lack this expertise but who want to capitalize on the significant market opportunity that exists in the us and canada commercialize we intend to commercialize the products that we inlicense and develop our substantial experience in launching and growing critical care brands in the us makes us an ideal partner for companies who lack this expertise and capability       publications  tenax therapeutics publications following is a list of available tenax publications by category levosimendan in cardiac surgery board of directors  tenax therapeutics board of directors dr ronald blanck chairman ronald r blanck do has served as a director since december  and as chairman since september  dr blanck has served as chairman of martin blanck  associates a federal health services consulting firm based in falls church va since january  he began his military career in  as a medical officer and battalion surgeon in vietnam retiring  years later as a lieutenant general and surgeon general of the us army and commander of the us army medical command he also served as commander of walter reed medical center and the north atlantic region medical command his background also includes serving as president of the university of north texas health science center at fort worth anthony ditonno anthony a ditonno has served as a director since december  since february  mr ditonno has served as chief executive officer of avantis medical systems inc a medical device company that develops and manufactures catheterbased endoscopic devices  from april  until december  mr ditonno was president and chief executive officer of neurogesx inc a biopharmaceutical company based in the san francisco bay area “neurogesx” during his time at neurogesx mr ditonno also served on its board of directors  mr ditonno has funded companies through a variety of financial arrangements including private and public financings partnerships and debt he has also been successful in gaining regulatory approvals in both the united states and european union previously he was executive vice president of marketing and sales at enteric medical technologies inc which was acquired by boston scientific company president and chief executive officer of lifesleep systems inc and vice president and general manager of olcassen pharmaceuticals which was sold to watson laboratories early in his career he held a variety of positions of increasing responsibility at rorer group inc rhône poulenc rorer and wyeth laboratories mr ditonno received an mba from drexel university and a bs in business administration from st joseph’s university james mitchum mr mitchum is an experienced highlyregarded pharmaceutical executive and has served as the chief executive officer of heart to heart international a nonprofit humanitarian organization since september  from  to july  mr mitchum served as president of the americas for eusa pharma usa inc where he oversaw the streamlining of that business as well as the development fda approval and successful launch of a pediatric oncology drug in  previously he served as president and chief executive officer of enturia inc a privately owned drugdevice company based in kansas city from  to  mr mitchum served as the president and chief executive officer of sanofiaventis group japan and he was chief executive for aventis pharma uk from  through  he has also worked in a variety of other senior financial roles mr mitchum currently serves as a director for nephrogenex inc a company developing drugs to treat kidney disease and has also served as a director on numerous private company and organization boards he holds an mba from the university of tennessee and a bs in business and math from milligan college gregory pepin gregory pepin has served as a director since august   from july  until april  he was engaged as a senior vice president at melixia sa “melixia” an investment management company based in switzerland  in that position he participated in the formation of vatea fund a stakeholder in our company and has served as a managing director of that fund since june   in may  he cofounded eos investment ltd “eos” an investment company based in the cayman islands which serves as investment manager of vatea fund and as investment manager and managing director of oxbt fund one of our principal stockholders  eos serves as the investment manager and the managing director for two other funds that are not affiliated with us  in may  mr pepin cofounded independent wealth management sa an investment management company based in switzerland and he has served as a financial analyst for the company since that time  from september  through the end of june  mr pepin was employed as a consultant in finance and insurance by winter  associates located in paris france  in july  mr pepin earned the degree of master of science and economy finance and actuaries from hec lausanne gerald proehl gerald t proehl has served as a director since april  currently mr proehl is a founder president ceo and director of dermata therapeutics llc a private biotechnology company from january  to january  mr proehl was the president chief executive officer and a director of santarus inc “santarus” a company that he helped to found in  from march  through december  mr proehl was president and chief operating officer of santarus and from april  to march  mr proehl was vice president marketing and business development of santarus mr proehl helped lead the sale of santarus to salix pharmaceuticals for  billion in january of  prior to joining santarus mr proehl was with hmr for  years where he served in various capacities including vice president of global marketing during his career at hmr he worked across numerous therapeutic areas including cns cardiovascular and gastrointestinal mr proehl currently serves on the board of directors of of sophiris bio inc a publicly traded company developing a latestage targeted treatment for benign prostatic hyperplasia and ritter pharmaceuticals inc a publicly traded company developing therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases mr proehl also serves on a number of private company boards including kinetek sports inc patara pharma llc and mdrejuvena inc mr proehl holds a bs in education from the state university of new york at cortland an ma in exercise physiology from wake forest university and an mba from rockhurst university chris a rallis chris a rallis has served as a director since december  mr rallis is an executiveinresidence at pappas ventures a life science venture capital firm based in durham nc from april  until june  he was president and chief executive officer of immunobiosciences inc a vaccine technology company formerly located in raleigh nc he has served as a consultant for duke university and panacos pharmaceuticals inc and is the former president and chief operating officer of triangle pharmaceuticals inc “triangle” which was acquired by gilead sciences in january  for approximately  million while at triangle he participated in  equity financings generating gross proceeds of approximately  million he was also primarily responsible for all business development activities which included a worldwide alliance with abbott laboratories and the inlicensing of  compounds earlier he served in various business development and legal management roles with burroughs wellcome co mr rallis serves on the boards of aeolus pharmaceuticals and adherex technologies and chairs the audit committee of both boards he received his ab degree in economics from harvard college and a jd from duke university microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft corporate overview  tenax therapeutics investor center corporate overview tenax therapeutics inc nasdaqtenx tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions recent news investor relations jesse baumgartner stern investor relations  jessesternircom tenxnasdaq cm stock quote  tenax therapeutics inc  bloomberg markets error could not add to watchlist x  watchlist tenax therapeutics inc tenxus nasdaq cm usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  hours ago tenax therapeutics provides regulatory update on levosimendan  tenax meets with fda to discuss positive mortality data and potential levosimendan nda submission  orion oyj orion group interim report januarymarch   tenax therapeutics announces review of strategic alternatives and business update  tenax therapeutics announces yearend  financial results and provides corporate update  tenax therapeutics to discuss yearend  financial results and provide business update  tenax therapeutics announces topline results from phase  levocts trial in cardiac surgery there are currently no press releases for this ticker please check back later profile tenax therapeutics inc is a biomedical product development company the company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics blood substitutes liquid ventilation and implanted glucose sensing address one copley parkwaysuite morrisville nc united states phone  website wwwoxybiomedcom executives board members michael b jebsen presidentinterim ceocfo nancy j hecox exec vpsecygeneral counsel show more corporate overview  tenax therapeutics investor center corporate overview tenax therapeutics inc nasdaqtenx tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions recent news investor relations jesse baumgartner stern investor relations  jessesternircom corporate overview  tenax therapeutics investor center corporate overview tenax therapeutics inc nasdaqtenx tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions recent news investor relations jesse baumgartner stern investor relations  jessesternircom tenax therapeutics provides regulatory update on levosimendan  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street tenax therapeutics provides regulatory update on levosimendan business wire jul    pm edt tenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today provides a regulatory update following discussions with the us food and drug administration fda and health canada regarding a regulatory path forward for levosimendan in may  the company participated in a prenda meeting with the fda to discuss the possibility of submitting an nda for levosimendan in two indications treatment of patients undergoing coronary artery bypass grafting cabg to reduce the risk of low cardiac output syndrome lcos and treatment of patients with acute decompensated heart failure adhf for improvement in symptoms after a review of further analyses the fda has requested an additional clinical trial given the size and scope of such a trial the company is reviewing clinical regulatory and financial options with regard to the levosimendan program in the us and canada the companys board of directors is continuing its review of strategic alternatives with the assistance of their financial advisors at ladenburg thalmann  co inc strategic alternatives under review include but are not limited to a merger a business combination a strategic investment into the company or a purchase license or other acquisition of assets this process may not result in any transaction and the company does not intend to disclose additional details unless and until it has entered into a specific transaction about levosimendan levosimendan is a calcium sensitizer that works through a unique triple mechanism of action it initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure it was discovered and developed by orion pharma orion corporation of espoo finland and is currently approved in over  countries for this indication and not available in the united states tenax therapeutics acquired the north american rights to develop and commercialize levosimendan from phyxius pharma if you liked this article you might like these  stocks under  could light up soon heres a technical look at how to trade several under  stocks that could trigger big breakout trades soon roberto pedone feb    pm est trending tesla is a cult stock jim cramer says can apple show amazon what earnings should look like ipod nano shuffle are dead here are  other discontinued apple products jim cramer nails starbucks big decline warns again of downside to  heres why snaps stock could be in for another big plunge on monday advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers tenax therapeutics leading criticalcare solutions tenax therapeutics is focused on identifying developing and commercializing products for the critical care market in the us alone more than five million hospitalized patients are treated in an intensive care setting annually according to the society of critical medicine     the levocts trial results were presented on sunday march   at the american college of cardiology th annual scientific session in washington dc primary results presentation focus on critical care given the high mortality morbidity and costs associated with the treatment of many intensive care patients we believe that there is a substantial opportunity to add value for patients physicians hospitals and ultimately shareholders   news jul   tenax therapeutics provides regulatory update on levosimendan may   tenax meets with fda to discuss positive mortality data and potential levosimendan nda submission apr   tenax therapeutics announces review of strategic alternatives and business update tenax therapeutics announces review of strategic alternatives and business updatehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballtenax therapeutics announces review of strategic alternatives and business updatebusiness wireapril  reblogsharetweetsharemorrisville ncbusiness wiretenax therapeutics inc tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today provided an update related to its business strategy the clinical development of its product candidates and its management team the company’s board of directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value and has formed a strategic committee of three independent board members to supervise management in this review in addition the company has engaged ladenburg thalmann  co inc a subsidiary of ladenburg thalmann financial services inc nyse mkt lts as its financial advisor to assist in the strategic review process including but not limited to a merger a business combination a strategic investment into the company or a purchase license or other acquisition of assets this process may not result in any transaction and the company does not intend to disclose additional details unless and until it has entered into a specific transaction as reported earlier the company continues to believe levosimendan is an effective and safe inotrope to increase cardiac output in patients at risk for or with perioperative low cardiac output accordingly the company plans to continue pursuing a regulatory filing in canada the company continues to evaluate the results of the levocts clinical trial and feedback provided by the fda in preparation for the prenda meeting with the fda to occur in may while simultaneously exploring additional strategic options and alternatives that might enhance stockholder value effective april   john kelley resigned as chief executive officer of the company and from the company’s board of directors but has agreed to provide consulting services to the company for a period of time following his resignation the company’s board of directors appointed michael jebsen the company’s current president and chief financial officer as interim chief executive officer effective immediately upon mr kelley’s resignation mr jebsen previously served as interim chief executive officer for the company from  to  ronald blanck chairman of the board of directors for the company said “we thank john for his contributions and wish him well for the future this development does not change the focus or direction of the company which remains dedicated to enhancing shareholder value through the development and commercialization of products for the critical care market and we have complete confidence in michael’s ability to lead the company once again during this transitional stage of its development”“i thank the board of directors for this opportunity and look forward to building upon the foundation established through our prior drug development experience to bolster the company’s product pipeline and commercialization efforts” said michael jebsenabout tenax therapeuticstenax therapeutics inc is a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market for more information visit wwwtenaxtheracomabout levosimendanlevosimendan is a calcium sensitizer that works through a unique triple mechanism of action it initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure it was discovered and developed by orion pharma orion corporation of espoo finland and is currently approved in over  countries for this indication and not available in the united states tenax therapeutics acquired the north american rights to develop and commercialize levosimendan from phyxius pharma inccaution regarding forwardlooking statementsthis news release contains certain forwardlooking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release the forwardlooking statements are subject to a number of risks and uncertainties including but not limited to matters beyond the company’s control that could lead to the company’s need for additional funding to continue to operate as a going concern risks associated with the company’s ability to manage operating expenses and obtain additional capital as needed the impact of significant reductions in the company’s operations on its ability to develop its product candidates or maintain compliance with laws and regulations relating to public companies the company’s ability to maintain compliance with nasdaq’s continued listing standards and policies and to maintain the listing and trading of its common stock on that exchange uncertainties inherent in the conduct of clinical studies and the risk that the company’s product candidates may not demonstrate adequate safety efficacy or tolerability in one or more clinical studies for approval by regulatory authorities the potential for the company to sell or license part or all of its assets the impact of management changes on the company’s business and unanticipated charges costs and expenditures not currently contemplated that may occur as a result of management changes and other risks and uncertainties as described in the company’s filings with the securities and exchange commission including in its annual report on form k filed on march   as well as its other filings with the sec the company disclaims any intent or obligation to update these forwardlooking statements beyond the date of this release statements in this press release regarding management’s future expectations beliefs goals plans or prospects constitute forwardlooking statements within the meaning of the private securities litigation reform act of view source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nexttrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insiderthis will be in everyones household by banyan hillsponsoredhere are the us targets north korea most likely wants to nukebusiness insiderthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderchevron and exxon mobil have a tough path ahead nyse traderyahoo finance videoengineer finds pattern makes millions in stocksmoney morningsponsoredstocks mixed after heavy earnings weektrump names john f kelly new chief of staff reince priebus outcnbcthe real reason overseas manufacturing is coming to americayahoo financehuman barbie takes off make up drs are speechlesskiwi reportsponsorednorth korea nd icbm test puts much of us in range expertsassociated pressmy bullish view on stocks hasnt changed one iota nyse traderyahoo finance videoblue apron bullish calls not all theyre cooked up to beyahoo financewhats the problem with joel osteenchurchleaderscomsponsoreda major player in the struggle for control of the sinaloa cartel just surrendered in the usbusiness insidertax cuts just got more likelyyahoo financetrump is acting suspicious because he ‘may be’ innocent fox news saysben i always hire a slew of lawyers when i havent done anything so it makes perfect sense 😂😂join the conversation  k tenax therapeutics provides regulatory update on levosimendan  business wire tenax therapeutics provides regulatory update on levosimendan july    pm eastern daylight time morrisville ncbusiness wiretenax therapeutics inc nasdaq tenx a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market today provides a regulatory update following discussions with the us food and drug administration fda and health canada regarding a regulatory path forward for levosimendan in may  the company participated in a prenda meeting with the fda to discuss the possibility of submitting an nda for levosimendan in two indications treatment of patients undergoing coronary artery bypass grafting cabg to reduce the risk of low cardiac output syndrome lcos and treatment of patients with acute decompensated heart failure adhf for improvement in symptoms after a review of further analyses the fda has requested an additional clinical trial given the size and scope of such a trial the company is reviewing clinical regulatory and financial options with regard to the levosimendan program in the us and canada the company’s board of directors is continuing its review of strategic alternatives with the assistance of their financial advisors at ladenburg thalmann  co inc strategic alternatives under review include but are not limited to a merger a business combination a strategic investment into the company or a purchase license or other acquisition of assets this process may not result in any transaction and the company does not intend to disclose additional details unless and until it has entered into a specific transaction about levosimendan levosimendan is a calcium sensitizer that works through a unique triple mechanism of action it initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure it was discovered and developed by orion pharma orion corporation of espoo finland and is currently approved in over  countries for this indication and not available in the united states tenax therapeutics acquired the north american rights to develop and commercialize levosimendan from phyxius pharma about tenax therapeutics tenax therapeutics inc is a specialty pharmaceutical company focused on identifying developing and commercializing products for the critical care market for more information visit wwwtenaxtheracom caution regarding forwardlooking statements this news release contains certain forwardlooking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release the forwardlooking statements are subject to a number of risks and uncertainties including but not limited to matters beyond the company’s control that could lead to delays in the clinical study delays in new product introductions and customer acceptance of these new products and other risks and uncertainties as described in the company’s filings with the securities and exchange commission including in its transition report on form k filed on march   its quarterly report on form q filed on may   as well as its other filings with the sec the company disclaims any intent or obligation to update these forwardlooking statements beyond the date of this release statements in this press release regarding management’s future expectations beliefs goals plans or prospects constitute forwardlooking statements within the meaning of the private securities litigation reform act of  contacts stern investor relations incwill o‘connor willsternircom release summary tenax therapeutics inc nasdaq tenx provides regulatory update on levosimendan following discussions with fda additional clinical trial needed contacts stern investor relations incwill o‘connor willsternircom search advanced news search advanced news search log in sign up tenax therapeutics inc nasdaqtenx files an k financial statements and exhibits  traders log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east» more equities indexes dow jonessp nasdaq tsx compftse » more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd» more currencies commodities goldcrude oil wticrude oil brentsilverplatinum» more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    equities    nasdaq    tenax therapeutics inc    tenx tenax therapeutics inc tenx add to my list    mes dernières consultmost popular manage my lists  delayed     pm  usd    p tenax therapeut  tenx files an k financial statements and exhibi p tenax therapeut  provides regulatory update on levosimendan  tenax therapeut  meets with fda to discuss positive mortality data  summaryquoteschartsnewscalendarcompanyfinancialsconsensusrevisions news summarymost relevantall newssector newstweets tenax therapeutics inc nasdaqtenx files an k financial statements and exhibits    pm cest send by mail  last name  name  from  to  you can enter multiple email addresses separated by commas message  required fields tenax therapeutics inc nasdaqtenx files an k financial statements and exhibitsitem  financial statements and exhibits d exhibits exhibit no description press release dated july   tenax therapeutics inc exhibitex  tenxexhtm press release dated july …to view the full exhibit click hereabout tenax therapeutics inc nasdaqtenx tenax therapeutics inc is a specialty pharmaceutical company the company is focused on identifying developing and commercializing products for the critical care market the company’s main product is levosimendan levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure levosimendan represents therapeutic modalities for the treatment of low cardiac output syndrome lcos septic shock and other critical care conditions the therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin c resulting in a positive inotropic effect which is not associated with substantial increases in oxygen demand opening of potassium channels in the vasculature smooth muscle resulting in a vasodilatory effect on all vascular beds and opening of mitochondrial potassium channels in cardiomyocytes resulting in a cardioprotective effect the post tenax therapeutics inc nasdaqtenx files an k financial statements and exhibits appeared first on market exclusive market exclusive  source market exclusive  latest news on tenax therapeutics inc p tenax therapeutics inc nasdaq  tenx files an k financial statements and e p tenax therapeutics  provides regulatory update on levosimendan  tenax therapeutics inc  submission of matters to a vote of security holders   tenax therapeutics  meets with fda to discuss positive mortality data and poten  tenax therapeutics  managements discussion and analysis of financial condition  tenax therapeutics inc nasdaq  tenx files an k departure of directors or   herersquos why concert pharmaceuti  cnce and tenax therapeutics inc nasda  tenax therapeutics  announces review of strategic alternatives and business upd  tenax therapeutics  announces yearend  financial results and provides corp  tenax therapeutics inc  investor network invites you to the tenax therapeutics  more news news from seekingalpha  tenax therapeutics tenx ceo john kelley on q  results  earnings call  tenax therapeutics reports fy results  midday gainers  losers  tenax therapeutics lead product candidate flunks latestate study shares pl  healthcare  top  gainers  losers   am financials  sales   ebit   m net income   m debt   yield   pe ratio   pe ratio  capi  sales   capi  sales  x capitalization  m more financials chart tenax therapeutics inc duration  auto  months  months  months  months  year  years  years  years max period  day week fullscreen chart technical analysis trends tenax therapeutics inc short termmidtermlong termtrendsbullishbearishbearish technical analysis income statement evolution please enable javascript in your browsers settings to use dynamic charts more financials consensus sell buy mean consensus buy number of analysts  average target price   spread  average target  consensus details eps revisions please enable javascript in your browsers settings to use dynamic charts more estimates revisions managers nametitlemichael b jebsen president ceo cfo  treasurer ronald r blanck chairman gregory pepin independent director chris a rallis independent director anthony a ditonno independent director more about the company sector and competitors st jancapitalization m tenax therapeutics inc incyte corporation  quintiles ims holdings inc  lonza group  celltrion inc  alkermes plc  more results traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners börse aktien kurse und nachrichtenbest tweets copyright   surperformance all rights reserved slave